Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
E. Gascoigne
Observed names:
E. GASCOIGNE,
E. W. Gascoigne,
E.W. Gascoigne,
Ernie Gascoigne,
Ernie W. Gascoigne
Institution:
Bio Products Laboratory (United Kingdom)
Observed institutions:
Bio Products Laboratory (United Kingdom),
Royal Surrey County Hospital,
The Royal Free Hospital,
Janssen (United Kingdom)
OpenAlex ID:
A5112025966
Ketoconazole Versus Nystatin Plus Amphotericin B for Fungal Prophylaxis in Severely Immunocompromised Patients
1982
·
I.M. Hann
, R. Corringham
, et al.
·
The Lancet
·
153
Production of human albumin solution: a continually developing colloid
2000
·
P. Matejtschuk
, C.H. Dash
, et al.
·
British Journal of Anaesthesia
·
110
The pharmacokinetics of ketoconazole in severely immunocompromised patients
1982
·
I. M. Hann
, H. G. Prentice
, et al.
·
Journal of Antimicrobial Chemotherapy
·
30
Experience of using human albumin solution 4·5% in 1195 therapeutic plasma exchange procedures
2010
·
C. Pusey
, C. Dash
, et al.
·
Transfusion Medicine
·
19
Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075)
2014
·
Clive H. Dash
, Kate R. Gillanders
, et al.
·
PLoS ONE
·
16
PDF
Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A
2011
·
A. DMOSZYNSKA
, K. KULICZKOWSKI
, et al.
·
Haemophilia
·
15
Clinical Experience with a New Solvent Detergent‐Treated Intravenous Immunoglobulin Free of Hypotensive Effects
1999
·
K. Chidwick
, P. Matejtschuk
, et al.
·
Vox Sanguinis
·
15
Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A
2010
·
A. DMOSZYNSKA
, A. HELLMANN
, et al.
·
Haemophilia
·
14
PDF
A retrospective survey on the safety of Replenine®, a high‐purity factor IX concentrate
2003
·
E. W. Gascoigne
, C. H. Dash
, et al.
·
Pharmacoepidemiology and Drug Safety
·
10
Solvent/detergent treatment does not alter the tolerance or uptake of human normal immunoglobulin for intramuscular injection
2001
·
G. P. Mould
, J. A. Sutton
, et al.
·
Vox Sanguinis
·
7
A retrospective survey on the safety of Replenate®, a high‐purity factor VIII concentrate
2004
·
E. W. Gascoigne
, C. H. Dash
, et al.
·
Pharmacoepidemiology and Drug Safety
·
4
Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov - NCT02247141)
2015
·
Clive Dash
, Ernie Gascoigne
, et al.
·
PLoS ONE
·
2
Technical Proficiency Examinations: A Brief Report.
1977
·
D. E. Loney
, E. Gascoigne
Show more works
View as search
Works count:
13
Citation count:
395
H-index:
9
I10-index:
9
Year
Topic
Type